Phase 3 Liver Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a primary liver or bile duct cancer confirmed by a tissue test (biopsy or pathology report).
• People who have cancer that has spread to the liver (from a non-lymphoma cancer), confirmed by a tissue test.
• People whose liver lesions appear on scans to be cancer spread, in the setting of a known cancer diagnosis and a previously clear liver scan.
• People diagnosed with hepatocellular carcinoma (a type of liver cancer) based on specific scan features, a raised AFP blood marker, and a history of cirrhosis or chronic hepatitis.
• People with 5 or fewer liver tumours that can be measured on a contrast-enhanced CT or MRI scan taken within the 90 days before joining the study.
• People whose liver tumour(s) measure 25 cm or smaller in size.
• People who have cancer outside the liver may still be considered, if the liver disease is judged by doctors to be the most life-threatening part of the illness.
• People whose liver tumours can all be covered within the planned radiation treatment area.
• People whose doctors have determined that surgery is not a suitable option for them, for medical or surgical reasons.
• People with a Zubrod Performance Score of 0 to 3 (a scale used by doctors to measure how much a person's daily activities are affected by illness — 0 means fully active, 3 means limited self-care).
• People aged over 18 years.
• People whose liver tumours are suitable for a procedure called TACE (a treatment that delivers chemotherapy directly to the tumour through the blood vessels).
• People who have previously had liver surgery or ablation treatment may still be considered.
• People who have finished chemotherapy at least 2 weeks before starting radiation therapy or TACE, and who are not expected to receive chemotherapy for at least 1 week after treatment ends (or at least 4 weeks for a specific drug type called anthracyclines).
• People with a life expectancy of more than 6 months.
• People who are able and willing to use appropriate contraception during the trial (applies to women who could become pregnant and to male participants).
• People who are willing and able to sign a consent form before joining the study.
• People whose recent blood test results (taken within 4 weeks of joining) meet the following levels: white blood cell count, platelet count, haemoglobin, bilirubin, clotting time, albumin, and liver enzyme levels all within the ranges required by the trial (confirm specific values with the trial site).

Who may not be able to join:

• People with severe cirrhosis or liver failure, rated as Child-Pugh score above B7 (a scoring system doctors use to assess liver disease severity — confirm with trial site).
• People whose liver tumour or metastasis is larger than 25 cm.
• People who have previously had radiation therapy to the same area of the body, where new radiation fields would overlap with the old ones.
• People with serious other health conditions that limit life expectancy to less than 6 months.
• People with active hepatitis or significant liver failure.
• People who are pregnant, breastfeeding, or could become pregnant and are not willing or able to use reliable contraception, as the treatments involved may be harmful to an unborn baby. Men who are sexually active and not willing or able to use contraception are also excluded.

Important: Always verify eligibility with the trial site directly before applying.